News coverage about AVEO Pharmaceuticals (NASDAQ:AVEO) has been trending somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AVEO Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 48.4853259561468 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news stories that may have effected Accern’s rankings:
- Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO) (finance.yahoo.com)
- AVEO Pharmaceuticals, Inc. (AVEO) projected to achieve earnings growth of -58.10% for this year (wallstreetinvestorplace.com)
- Radar for In Play Stock – AVEO Pharmaceuticals Inc (NASDAQ: AVEO) (stockspen.com)
- Aveo Pharmaceuticals (AVEO): Stock Valuation Review (emnnews.com)
- Stock Bulletin: Aveo Pharmaceuticals (AVEO) (emnnews.com)
AVEO Pharmaceuticals stock traded down $0.27 during mid-day trading on Thursday, hitting $2.36. The company’s stock had a trading volume of 3,438,539 shares, compared to its average volume of 1,712,653. The firm has a market capitalization of $310.24, a price-to-earnings ratio of -14.75 and a beta of 1.32. AVEO Pharmaceuticals has a 1 year low of $0.55 and a 1 year high of $4.24. The company has a debt-to-equity ratio of -0.45, a quick ratio of 1.56 and a current ratio of 1.56.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.